Ridaforolimus Approval Status
Ridaforolimus is an investigational oral mTOR inhibitor in development for the treatment of metastatic soft-tissue or bone sarcomas.
In June 2012, Merck & Co., Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for ridaforolimus had not been approved.
Development Status and FDA Approval Process for ridaforolimus
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.